Table 1.
Characteristics of 29 patients with ocular vascular occlusion with FVL or PTG G20210A variant
| Serial number | Sex | Age (years) | Type of occlusion | FVL | PTG | First thrombotic event?# | Other thrombotic events?$ | Known family history of thrombosis?† | Visual outcome in given eye? | Estrogen/testosterone/clomiphene use?‡ |
|---|---|---|---|---|---|---|---|---|---|---|
| FVL | ||||||||||
| 1 | Male | 33 | RAO | Yes | No | Yes | No | Decreased | No | |
| 2 | Male | 72 | CRVO | Yes | No | Yes | No | No follow-up | No | |
| 3 | Male | 55 | CRVO | Yes | No | No (DVT) | Yes | No change | No | |
| 4 | Male | 64 | NA-AION | Yes | No | Yes | No | Decreased | No | |
| 5 | Male | 50 | CRVO | Yes | No | Yes | No | Blind | No | |
| 6 | Male | 41 | CRVO | Yes | No | Yes | No | No follow-up | No | |
| 7 | Male | 43 | CRVO | Yes | No | Yes | No | No follow-up | No | |
| 8 | Female | 52 | AF | Yes | No | Yes | Miscarriages | Yes | No change | No |
| 9 | Female | 68 | CRVO | Yes | No | Yes | Miscarriages | No | Decreased | No |
| 10 | Female | 38 | CRVO | Yes | No | Yes | Miscarriages | Yes | No change | Clomiphene |
| 11 | Female | 69 | CRVO | Yes | No | Yes | AVN, miscarriage | No | Blind | No |
| 12 | Female | 52 | CRVO | Yes | No | Yes | Yes | Decreased | No | |
| 13 | Female | 60 | CRVO | Yes | No | Yes | Yes | No change | Estrogen | |
| 14 | Female | 54 | CRVO | Yes | No | Yes | No | No change | Estrogen | |
| 15 | Female | 45 | RAO | Yes | No | Yes | Miscarriages | No | Decreased | No |
| 16 | Female | 25 | CRVO | Yes | No | Yes | Multifocal ON | No | Decreased | Estrogen |
| PTG | ||||||||||
| 1 | Male | 69 | NA-AION | No | Yes | Yes | Stroke | Yes | Decreased | No |
| 2 | Male | 68 | AF | No | Yes | No (DVT) | Yes | Blind | No | |
| 3 | Male | 59 | CRVO | No | Yes | Yes | No | Decreased | Testosterone | |
| 4 | Male | 50 | NA-AION | No | Yes | Yes | TIA | Yes | No change | No |
| 5 | Male | 29 | RAO | No | Yes | Yes | No | No follow-up | No | |
| 6 | Female | 63 | BRVO | No | Yes | Yes | Yes | Decreased | No | |
| 7 | Female | 58 | CRVO | No | Yes | Yes | No | Decreased | No | |
| 8 | Female | 82 | CRVO | No | Yes | Yes | No | Blind | No | |
| 9 | Female | 16 | CRVO | No | Yes | Yes | Yes | Decreased | No | |
| 10§ | Female | 77 80 |
RAO CRVO |
No | Yes | Yes | Miscarriages | No | Blind No change |
Estrogen Estrogen |
| 11 | Female | 75 | NA-AION | No | Yes | No (DVT) | Ischemic colitis | No | Decreased | Estrogen |
| 12 | Female | 56 | NA-AION | No | Yes | No (DVT-PE) | AVN | Yes | Blind | No |
| FVL + PTG | ||||||||||
| 1 | Female | 73 | BRVO | Yes | Yes | No (DVT) | Miscarriages | No | Decreased | No |
Notes:
First thrombotic event in patient, defined as no previous DVT or PE.
Other thrombotic events in patient, defined as events likely resulting from a hypercoagulable state other than DVT or PE, such as miscarriages, AVN, multifocal ON, stroke, or ischemic colitis.
Known family history of thrombosis, defined as an immediate family member with previous DVT or PE.
Use of estrogen, clomiphene, or testosterone therapy at the time of ocular event.
One patient with PTG mutation with two separate ocular events, RAO at the age of 77 years in the left eye and RVO at the age of 80 years in the right eye.
Abbreviations: AF, amaurosis fugax; AVN, avascular necrosis; BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; DVT, deep venous thrombosis; FVL, factor V Leiden; NA-AION, nonarteritic anterior ischemic optic neuropathy; ON, osteonecrosis; PE, pulmonary embolism; PTG, prothrombin gene; RAO, retinal artery occlusion; RVO, retinal vein occlusion; TIA, transient ischemic attack.